September news: MHRA licences will allow UK industry to manufacture innovative medicines

How will the newly MHRA licenced CGT Catapult manufacturing centre support developers in the UK?

In this newsletter:

  • How will the newly MHRA licenced CGT Catapult manufacturing centre support developers in the UK?
  • What are the implications of cost-utility analysis and budget impact methodologies? Listen to our heath economics webinar.
  • Find out about preclinical development of cell-based medicinal products for European markets